Model and product identifier consistency: the risk of a self-contradicting dossier

1. Key takeaways

Paragraph 11 of the notes on the expedited listing application scheme states the position plainly: where the model or product identifier is expressed inconsistently across the application dossier, the applicant must submit additional information demonstrating the equivalence of the different expressions, covering both the device description and the brief specifications, and failure to provide that information may result in an unsuccessful application. The force of the rule lies in what it does not examine. It does not weigh the quality of the product; it examines whether the file agrees with itself. A dossier that contradicts itself may be stopped before technical review begins.

Because the test is formal, it is also cheap to pass and expensive to fail. The work required is a cross-reference table and a single writing convention, neither of which depends on the technical merits of the product.

• The rule is about self-consistency. Identifiers must match across the whole dossier, not merely on the front page.
• Equivalence must be argued on two dimensions. Device description and brief specifications, not a bare assertion that the identifiers are the same.
• The expedited scheme is where the rule bites hardest. Speed is the benefit being sought, and a supplementary request consumes exactly that benefit.
• Consistency is a continuing duty. Change notifications under GN-10 raise the same question as the original application.
• Three numbering systems is the usual cause. Internal item numbers, foreign approval model numbers and the model entered on the Hong Kong, China form.

2. Legal basis

The rule sits in the notes accompanying the expedited listing application scheme, at paragraph 11. GN-02 and GN-06 govern application forms and dossier preparation for general medical devices and in vitro diagnostic devices respectively, and both require the identifier to be stated consistently. TR-002 governs the summary, which is where the device description and specifications are set out, and GN-10 governs changes to listed devices.

The rule is short and the consequence is explicit, which is unusual in a system built largely on guidance notes. That combination is a signal: the point is treated as a threshold condition rather than a matter of reviewer judgement, and the applicant is expected to have dealt with it before submission.

3. Expert insights

Inconsistency usually comes from three numbering systems. The manufacturer’s internal item number, the model shown on the foreign approval document, and the model entered on the Hong Kong, China application form are frequently different strings. Unless the dossier establishes a cross-reference, the reviewer encounters what appear to be three different devices, and the reviewer cannot be expected to infer that they are the same product.

The rule is most damaging inside the expedited scheme. The benefit of the scheme is speed, and a request for further information consumes precisely that benefit. The issue under paragraph 11 is a formal defect, but its consequence is the same as a substantive one: the timeline moves, and in a competitive tender the movement can decide the outcome.

Consistency is a continuing obligation, not a first-application task. When a change is notified under GN-10, an inconsistency between the new identifier expression and the original listing triggers the same requirement for an equivalence statement. Applicants who treat the cross-reference table as a one-off artefact rebuild it every time a variant is added.

The equivalence statement has its own format. Equivalence must be argued from two dimensions, the device description and the brief specifications. Writing that the two expressions are the same does not constitute an argument; the statement has to show, dimension by dimension, that the technical content behind each expression is identical.

A single convention is cheaper than a reconciliation exercise. The most economical control is to decide one writing for each identifier and use it everywhere, permitting the other writings to appear only in the cross-reference table. The alternative, reconciling variants across a dossier at the end of drafting, is the more expensive path and the one that produces missed instances.

4. Practical recommendations

• Build one global cross-reference table. Place four columns side by side, internal item number, foreign model, application form model and label model, on the first page of the dossier.
• Use one writing throughout. Every location in the dossier uses the single form fixed in the table; other forms appear only in the table itself.
• Keep an equivalence statement template ready. Where a different expression is genuinely necessary, draft the statement in the two-column structure of device description and brief specifications.
• Re-check at every change notification. Each time a change is notified under GN-10, verify that the identifier expression still matches the original listing.
• Page-check before submission. Where the expedited scheme is used, read the dossier page by page for identifier expressions, since that is where the risk is concentrated.

5. Verification checklist

• □ A four-column cross-reference table covering internal item number, foreign model, application form model and label model has been established.
• □ One model writing is used consistently throughout the dossier.
• □ An equivalence statement template covering device description and brief specifications is prepared.
• □ The expedited scheme application has been checked page by page for identifier expressions.
• □ Identifier expressions in previous change notifications have been reviewed.
• □ The cross-reference table has been submitted with the first page of the dossier.

Regulatory information verified as at 29 October 2026. The legislation, guidance and effective dates described in this article are limited to the content published by the official sources listed under legal basis on that date; where those sources are updated, the latest published version prevails.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Hong Kong, China. Our team prepares MDACS-compliant dossiers, coordinates evidence of reference approvals and ISO 13485 certificates, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com